Advertisement
Advertisement

CGON

CGON logo

CG Oncology, Inc. Common stock

52.00
USD
Sponsored
-1.42
-2.65%
Jan 30, 16:00 UTC -5
Closed
exchange

After-Market

52.01

+0.01
+0.02%

CGON Earnings Reports

Positive Surprise Ratio

CGON beat 3 of 8 last estimates.

38%

Next Report

Date of Next Report
Mar 26, 2026
Estimate for Q4 25 (Revenue/ EPS)
$484.50K
/
-$0.62
Implied change from Q3 25 (Revenue/ EPS)
-70.92%
/
+10.71%
Implied change from Q4 24 (Revenue/ EPS)
+6.25%
/
+29.17%

CG Oncology, Inc. Common stock earnings per share and revenue

On Nov 14, 2025, CGON reported earnings of -0.56 USD per share (EPS) for Q3 25, beating the estimate of -0.57 USD, resulting in a 0.21% surprise. Revenue reached 1.67 million, compared to an expected 66.61 thousand, with a 2401.28% difference. The market reacted with a +8.61% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 17 analysts forecast an EPS of -0.62 USD, with revenue projected to reach 484.50 thousand USD, implying an increase of 10.71% EPS, and decrease of -70.92% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

logo
Regeneron Pharmaceuticals Inc
Report Date
Jan 30, 2026 For Q4 25
Estimate
$10.84
Actual
$11.44
Surprise
+5.52%
logo
Nurix Therapeutics, Inc. Common stock
Report Date
Jan 28, 2026 For Q4 25
Estimate
-$0.88
Actual
-$0.82
Surprise
+7.66%
FAQ
For Q3 2025, CG Oncology, Inc. Common stock reported EPS of -$0.56, missing estimates by 0.21%, and revenue of $1.67M, 2401.28% above expectations.
The stock price moved up 8.61%, changed from $37.76 before the earnings release to $41.01 the day after.
The next earning report is scheduled for Mar 26, 2026.
Based on 17 analysts, CG Oncology, Inc. Common stock is expected to report EPS of -$0.62 and revenue of $484.50K for Q4 2025.
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement